Corcept Therapeutics (CORT) Deferred Taxes (2017 - 2026)

Corcept Therapeutics has disclosed Deferred Taxes across 10 years of filings, most recently posting -$13.1 million for Q1 2026.

• Deferred Taxes for Q1 2026 came in at -$13.1 million, up 4.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$36.9 million (up 20.95% YoY), and the FY2025 annual result was -$37.5 million, up 6.6% from the prior year.
• Deferred Taxes came in at -$13.1 million for Q1 2026 at Corcept Therapeutics, up from -$15.2 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $9.1 million in Q3 2025 to a low of -$17.8 million in Q2 2025.
• The 5-year median for Deferred Taxes is -$9.9 million (2022), against an average of -$9.1 million.
• Across the five-year window, Deferred Taxes tumbled 678.8% in 2022 and jumped 159.93% in 2025, its largest moves.
• Corcept Therapeutics' Deferred Taxes stood at -$4.5 million in 2022, then climbed by 17.8% to -$3.7 million in 2023, then retreated by 5.07% to -$3.9 million in 2024, then tumbled by 293.52% to -$15.2 million in 2025, then climbed by 13.65% to -$13.1 million in 2026.
• The last three Deferred Taxes figures came in at -$13.1 million (Q1 2026), -$15.2 million (Q4 2025), and $9.1 million (Q3 2025), per Business Quant data.